Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT plus puterizumab for non-small cell lung cancer with intrapulmonary metastases
ChiCTR2400085132Phase 2Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pucotenlimab in non-small cell lung cancer (NSCLC), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Tumor response rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
pucotenlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400085132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085132.